# Kayentis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kayentis

- Industry: Software
- Headquarters: France
- Website: www.kayentis.com
- Total disclosed funding: $13M
- Latest round: Series E (Jan 15, 2015)
- Investors on record: 5

## About

Kayentis, SAS is a French company specializing in electronic Clinical Outcome Assessments (eCOA) to enhance clinical trials with user-friendly technology solutions for patient-reported outcomes.Founded in 2003 in France, Kayentis, SAS specializes in electronic Clinical Outcome Assessments (eCOA). The company has successfully completed 12 deals and recently raised EUR 2.20 mn in funding from Bpifrance, Extens, and LBO France. Kayentis operates from multiple global locations, including key markets in North America, Europe, and Asia. The founder’s history includes previous engagements in the clinical trials industry, contributing valuable expertise to the company.Kayentis specializes in electronic Clinical Outcome Assessments (eCOA) designed to enhance clinical trials across a wide range of therapeutic areas. Their core offerings include user-friendly technology solutions that facilitate the collection and management of patient-reported outcomes, ensuring high-quality data to inform clinical decisions. Kayentis has developed customized solutions for over 200 indications, catering specifically to diverse patient populations, from pediatrics to the elderly. The company serves pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) globally, with operations in key markets including North America, Europe, and Asia. Their eCOA solutions address critical needs in clinical trials, such as improving patient engagement and streamlining data capture processes.Kayentis generated revenue of EUR 18,855,986.70 in 2023, with an EBITDA of EUR 661,847. The company’s revenue primarily comes from B2B transactions with pharmaceutical and biotechnology companies, as well as CROs, for its eCOA services, involving project-based engagements and long-term partnerships where clients pay for tailored software solutions and data management services necessary for their clinical trials.Kayentis plans to leverage recent funding of EUR 2.20 mn to drive the development of new eCOA products designed for specific therapeutic areas expected to launch in the upcoming quarters. The company aims to expand its market presence in Asia and North America by 2025, enhancing its service offerings to meet the growing demand for efficient clinical trial solutions. Following the recent exit of XAnge Private Equity from its investment, Kayentis is positioning itself for sustainable growth by focusing on strategic partnerships and technology innovation.

## Funding rounds

- Series E, Jan 15, 2015, $1.5M — Seventure Partners, Extens, Lénapart, KCE
- Series D, Oct 25, 2013, $0.7M — Seventure Partners, XAnge, KCE
- Series D, Jun 22, 2011, $2.2M — Seventure Partners, XAnge, KCE
- Series C, Nov 21, 2007, $5.8M — Seventure Partners, XAnge
- Series A, Feb 20, 2006, $2.4M — XAnge

## Investors

- XAnge (https://capitalatlas.ai/funds/xange) — Series A, Series C, Series D
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series C, Series D, Series E
- KCE — Series D, Series E
- Extens (https://capitalatlas.ai/funds/extens) — Series E
- Lénapart — Series E